<DOC>
	<DOCNO>NCT01801033</DOCNO>
	<brief_summary>Background : - Hypothyroidism condition cause loss function thyroid gland . The thyroid gland produce two hormone , T4 T3 . These hormone control metabolism function many organ . Lack energy , depression , constipation common symptom hypothyroidism . T4 convert T3 , active form thyroid hormone , two enzyme call deiodinases . People hypothyroidism treat synthetic T4 hormone , enzymes convert T3 . This treatment usually effective , people continue symptom even treatment . Some researcher think may cause problem enzymes convert T4 T3 . They want look enzyme regulate level T4 T3 blood . They use drug block action one two enzyme . Objectives : - To look thyroid hormone enzyme block affect hypothyroidism treatment medication . Eligibility : - Individuals least 18 year age hypothyroidism thyroid hormone replacement therapy . Design : - The study consist one screening visit , 9 day inpatient hospital admission , follow-up visit 2 week discharge . - Participants screen physical exam medical history . They provide blood sample . - Participants receive balanced-diet meal take home 2 day enter hospital . They continue diet hospital . - During inpatient stay , participant monitor regular blood test . They follow procedure : - Continued thyroid hormone replacement 9 day . - Drug block thyroid enzyme 7 day . - Metabolism test , room temperature change , day 1 , 2 , 5 , 8 , 9 . - Measurements body fat day 2 , 5 , 8 . - Blood glucose test day 1 9 . - Muscle contraction test day 1 , 2 , 4 , 5 , 8 , 9 . - Heart image study day 2 , 5 , 8 . - Optional skeletal muscle fat tissue biopsy day 1 9 . - There follow-up visit 2 week leave hospital . Participants final physical exam provide blood sample .</brief_summary>
	<brief_title>Effects Thyroid Hormone Enzyme Blocking Hypothyroidism</brief_title>
	<detailed_description>Thyroid hormone action important regulator metabolism function many organ . The active form thyroid hormone T3 , blood tissue level result secretion T3 precursor , thyroxine ( T4 ) , thyroid gland , peripheral conversion T4 T3 , degradation hormone . In hypothyroid patient ( particularly patient underwent total thyroidectomy ) , level T3 entirely dependent exogenously administer T4 ( Levothyroxine , L-T4 ) convert T3 inactive form , rT3 , enzymes call deiodinases . This complex system partially study human little known correlation circulating level T3 end-organ target tissue thyroid hormone action . The aim protocol characterize contribution two activating deiodinases ( type-1 type-2 ) blood level biological effect T3 . To achieve goal intend study hypothyroid patient treated adequate replacement L-T4 therapy simultaneously block activity type-1 deiodinase propylthiouracil ( PTU ) . Twenty hypothyroid patient underwent total thyroidectomy affect hypothyroidism L-T4 therapy normal TSH value recruit . After enrollment study , patient eligibility determine outpatient visit . Patients admit NIH Clinical Center 9-day period receive PTU dose 200 mg four time daily seven day . During hospitalization research protocol , follow study perform : serial blood sample circulate thyroid hormone obtain pharmacokinetic parameter T3 , lipid , glucose insulin ; body composition ; rest energy expenditure room temperature exposure mild cold ; echocardiogram EKG ; skeletal muscle strength measurement cardiac MRI . The result obtain study help characterize effect thyroid hormone metabolism , may lead important information optimize thyroid hormone replacement therapy treatment hypothyroidism .</detailed_description>
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PARTICIPANT INCLUSION CRITERIA : Study subject adult old 18 year endogenous thyroid hormone production ( i.e . status post total thyroidectomy , individual residual remnant great 2 mL , uptake thyroid gland less 5 % therapy 123I uptake scan ) LT4 replacement minimum dose 1.6 microg/Kg steady state euthyroidism . EXCLUSION CRITERIA : 1 . &lt; TAB &gt; Thyroid uptake &gt; 5 % 24 hour ( 123 ) I thyroid scan replacement therapy ( patient thyroid gland residue &gt; 2 mL ultrasound ) . 2 . &lt; TAB &gt; Patients lipid disorder require pharmacologic intervention . 3 . &lt; TAB &gt; Any elevation AST ALT upper limit normal range . 4 . &lt; TAB &gt; Any reduction WBC count lower limit normal range . 5 . &lt; TAB &gt; History , and/or current diabetes mellitus ( fast glucose &gt; 126 mg/dL current pharmacologic treatment ) . 6 . &lt; TAB &gt; Hypertension require pharmacologic intervention . 7 . &lt; TAB &gt; Female patient hormonal contraceptive breastfeed . 8 . &lt; TAB &gt; Use beta blocker medication amiodarone . 9 . &lt; TAB &gt; Pregnancy ( woman childbearing age must negative pregnancy test prior inclusion ) . 10 . &lt; TAB &gt; History vasculitis , viral hepatitis ( except A ) , granulocytopenia . 11 . &lt; TAB &gt; Known allergy serious adverse event PTU . 12 . &lt; TAB &gt; Current use prescription medication certain nonprescription medication dietary supplement know affect thyroid function and/or metabolism , alter pharmacokinetics PTU . Should study volunteer receive pharmacologic intervention clinical pharmacist consult evaluate potential drugdrug interaction . 13 . &lt; TAB &gt; Presence persistent diarrhea malabsorption syndrome would interfere patient ability adequately absorb medication . 14 . &lt; TAB &gt; Inability obtain venous access sample collection , basal hemoglobin less equal 12 g/dl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 29, 2013</verification_date>
	<keyword>Trioodothyronine ( T3 )</keyword>
	<keyword>Thyroid Hormone Action</keyword>
	<keyword>Deiodinases</keyword>
	<keyword>Hypothyroid</keyword>
	<keyword>Propylthiouracil ( PTU )</keyword>
</DOC>